Abstract: The present invention provides methods of preparing a MK2 inhibitor, and intermediates related thereto.
Type:
Grant
Filed:
January 14, 2021
Date of Patent:
May 23, 2023
Assignee:
Celgene CAR LLC
Inventors:
Gregg Brian Feigelson, Maryll E. Geherty, Richard Martin Heid, Jr., Mohit Kothare, Hon-Wah Man, Alexander L. Ruchelman, John F. Traverse, Kelvin Hin-Yeong Yong, Chengmin Zhang
Abstract: The present invention provides compounds, compositions thereof, and methods of using the same.
Type:
Grant
Filed:
February 27, 2020
Date of Patent:
February 21, 2023
Assignee:
Celgene CAR LLC
Inventors:
Matthew David Alexander, Claudio Chuaqui, John Malona, Joseph John McDonald, Yike Ni, Deqiang Niu, Russell C. Petter, Juswinder Singh, Chittari Pabba
Abstract: The present invention relates to enzyme inhibitors. More specifically, the present invention relates to ligand-directed covalent modification of proteins; method of designing same; pharmaceutical formulation of same; and method of use.
Type:
Grant
Filed:
February 2, 2017
Date of Patent:
January 3, 2023
Assignee:
Celgene CAR LLC
Inventors:
Russell C. Petter, Charles F. Jewell, Kwangho Lee, Aravind Prasad Medikonda, Deqiang Niu, Lixin Qiao, Juswinder Singh, Zhendong Zhu
Abstract: The present invention provides 2,4-disubstituted pyrimidine compounds useful as kinase inhibitors, pharmaceutically acceptable compositions thereof, and methods of using the same.
Type:
Grant
Filed:
March 20, 2020
Date of Patent:
June 7, 2022
Assignee:
Celgene CAR LLC
Inventors:
Juswinder Singh, Russell C. Petter, Richland Wayne Tester, Arthur F. Kluge, Hormoz Mazdiyasni, William Frederick Westlin, III, Deqiang Niu, Lixin Qiao
Abstract: The present invention provides a salt form and compositions thereof, which are useful as an inhibitor of EGFR kinases and which exhibits desirable characteristics for the same.
Type:
Grant
Filed:
February 21, 2020
Date of Patent:
April 5, 2022
Assignee:
Celgene CAR LLC
Inventors:
Mei Lai, Steven Richard Witowski, Richland Wayne Tester, Kwangho Lee
Abstract: The present invention provides compounds of formula V: or pharmaceutically acceptable salts thereof, useful as inhibitors of MK2 kinases, compositions thereof, and methods of using the same.
Type:
Grant
Filed:
November 19, 2018
Date of Patent:
August 24, 2021
Assignee:
Celgene CAR LLC
Inventors:
Matthew David Alexander, Joseph John McDonald, Yike Ni, Deqiang Niu, Russell C. Petter, Lixin Qiao, Juswinder Singh, Tao Wang, Zhendong Zhu
Abstract: The present invention provides a solid form and compositions thereof, which are useful as an inhibitor of EGFR kinases and which exhibit desirable characteristics for the same.
Abstract: The present invention provides methods of preparing a MK2 inhibitor, and intermediates related thereto.
Type:
Grant
Filed:
March 15, 2018
Date of Patent:
January 19, 2021
Assignee:
Celgene CAR LLC
Inventors:
Gregg Brian Feigelson, Maryll E. Geherty, Richard Martin Heid, Jr., Mohit Kothare, Hon-Wah Man, Alexander L. Ruchelman, John F. Traverse, Kelvin Hin-Yeong Yong, Chengmin Zhang
Abstract: The present invention provides 2,4-diaminopyrimidines, and/or pharmaceutically acceptable compositions thereof, as kinase inhibitors.
Type:
Grant
Filed:
June 1, 2018
Date of Patent:
November 10, 2020
Assignee:
Celgene CAR LLC
Inventors:
Juswinder Singh, Russell C. Petter, Richland Wayne Tester, Arthur F. Kluge, Hormoz Mazdiyasni, William Frederick Westlin, III, Deqiang Niu, Lixin Qiao
Abstract: The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.
Type:
Grant
Filed:
January 23, 2019
Date of Patent:
September 15, 2020
Assignees:
Celgene CAR LLC, Sanofi
Inventors:
Laura Akullian D'Agostino, Robert Tjin Tham Sjin, Deqiang Niu, Joseph John McDonald, Zhendong Zhu, Haibo Liu, Hormoz Mazdiyasni, Russell C. Petter, Juswinder Singh, Matthieu Barrague, Alexandre Gross, Mark Munson
Abstract: The invention relates to protein conjugates that contain a protein kinase containing a cysteine residue in the ATP binding site and an inhibitor that is covalently and irreversibly bonded to said cysteine residue, such that the activity of the protein kinase is irreversibly inhibited. The invention also relates to compounds that irreversibly inhibit protein kinases.
Type:
Grant
Filed:
July 18, 2016
Date of Patent:
May 26, 2020
Assignee:
Celgene CAR LLC
Inventors:
Juswinder Singh, Russell Colyn Petter, Deqiang Niu, Lixin Qiao, Arthur Kluge, Roy Lobb, Shomir Ghosh, Zhendong Zhu
Abstract: The present invention provides substituted pyrido[2,3-d]pyrimidine compounds useful as inhibitors of protein kinases, pharmaceutically acceptable compositions thereof, and methods of using the same.
Type:
Grant
Filed:
August 28, 2018
Date of Patent:
April 14, 2020
Assignees:
Celgene CAR LLC, Sanofi
Inventors:
Laura Akullian D'Agostino, Robert Tjin Tham Sjin, Deqiang Niu, Joseph John McDonald, Zhendong Zhu, Haibo Liu, Hormoz Mazdiyasni, Russell C. Petter, Juswinder Singh, Matthieu Barrague, Alexandre Gross, Mark Munson, Darren Harvey, Andrew Scholte, Sachin Maniar
Abstract: The present invention provides 2,4-disubstituted pyrimidine compounds useful as kinase inhibitors, pharmaceutically acceptable compositions thereof, and methods of using the same.
Type:
Grant
Filed:
June 29, 2018
Date of Patent:
March 24, 2020
Assignee:
Celgene CAR LLC
Inventors:
Juswinder Singh, Russell C. Petter, Richland Wayne Tester, Arthur F. Kluge, Hormoz Mazdiyasni, William Frederick Westlin, III, Deqiang Niu, Lixin Qiao
Abstract: The present invention provides compounds, compositions thereof, and methods of using the same.
Type:
Grant
Filed:
April 4, 2019
Date of Patent:
March 3, 2020
Assignee:
Celgene CAR LLC
Inventors:
Matthew David Alexander, Claudio Chuaqui, John Malona, Joseph John McDonald, Yike Ni, Deqiang Niu, Russell C. Petter, Juswinder Singh, Chittari Pabba